BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 20501908)

  • 61.
    Higashi T; Nishii R; Kagawa S; Kishibe Y; Takahashi M; Okina T; Suzuki N; Hasegawa H; Nagahama Y; Ishizu K; Oishi N; Kimura H; Watanabe H; Ono M; Saji H; Yamauchi H
    Ann Nucl Med; 2018 Apr; 32(3):206-216. PubMed ID: 29388083
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dosimetry and efficacy of a tau PET tracer [
    Ohnishi A; Akamatsu G; Ikari Y; Nishida H; Shimizu K; Matsumoto K; Aita K; Sasaki M; Yamamoto Y; Yamane T; Senda M
    Ann Nucl Med; 2023 Feb; 37(2):108-120. PubMed ID: 36411357
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB.
    Ito H; Shinotoh H; Shimada H; Miyoshi M; Yanai K; Okamura N; Takano H; Takahashi H; Arakawa R; Kodaka F; Ono M; Eguchi Y; Higuchi M; Fukumura T; Suhara T
    Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):745-54. PubMed ID: 24233004
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351.
    Lockhart SN; Baker SL; Okamura N; Furukawa K; Ishiki A; Furumoto S; Tashiro M; Yanai K; Arai H; Kudo Y; Harada R; Tomita N; Hiraoka K; Watanuki S; Jagust WJ
    PLoS One; 2016; 11(6):e0158460. PubMed ID: 27355840
    [TBL] [Abstract][Full Text] [Related]  

  • 65. In Vivo Comparison of Tau Radioligands
    Betthauser TJ; Lao PJ; Murali D; Barnhart TE; Furumoto S; Okamura N; Stone CK; Johnson SC; Christian BT
    J Nucl Med; 2017 Jun; 58(6):996-1002. PubMed ID: 27856627
    [TBL] [Abstract][Full Text] [Related]  

  • 66. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
    Bailly M; Ribeiro MJ; Vercouillie J; Hommet C; Gissot V; Camus V; Guilloteau D
    Clin Nucl Med; 2015 Feb; 40(2):e111-6. PubMed ID: 25549345
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Parametric estimation of reference signal intensity in the quantification of amyloid-beta deposition: an
    Wang M; Yan Z; Zhang H; Lu J; Li L; Yu J; Wang J; Matsuda H; Zuo C; Jiang J;
    Quant Imaging Med Surg; 2021 Jan; 11(1):249-263. PubMed ID: 33392026
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction.
    Brendel M; Högenauer M; Delker A; Sauerbeck J; Bartenstein P; Seibyl J; Rominger A;
    Neuroimage; 2015 Mar; 108():450-9. PubMed ID: 25482269
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Quantification of [
    Golla SS; Verfaillie SC; Boellaard R; Adriaanse SM; Zwan MD; Schuit RC; Timmers T; Groot C; Schober P; Scheltens P; van der Flier WM; Windhorst AD; van Berckel BN; Lammertsma AA
    J Cereb Blood Flow Metab; 2019 Nov; 39(11):2172-2180. PubMed ID: 29897009
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.
    Lister-James J; Pontecorvo MJ; Clark C; Joshi AD; Mintun MA; Zhang W; Lim N; Zhuang Z; Golding G; Choi SR; Benedum TE; Kennedy P; Hefti F; Carpenter AP; Kung HF; Skovronsky DM
    Semin Nucl Med; 2011 Jul; 41(4):300-4. PubMed ID: 21624563
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates.
    Dugger BN; Clark CM; Serrano G; Mariner M; Bedell BJ; Coleman RE; Doraiswamy PM; Lu M; Fleisher AS; Reiman EM; Sabbagh MN; Sadowsky CH; Schneider JA; Zehntner SP; Carpenter AP; Joshi AD; Mintun MA; Pontecorvo MJ; Skovronsky DM; Sue LI; Beach TG
    J Neuropathol Exp Neurol; 2014 Jan; 73(1):72-80. PubMed ID: 24335535
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evaluation of Dosimetry, Quantitative Methods, and Test-Retest Variability of
    Bullich S; Barret O; Constantinescu C; Sandiego C; Mueller A; Berndt M; Papin C; Perrotin A; Koglin N; Kroth H; Pfeifer A; Tamagnan G; Madonia J; Seibyl JP; Marek K; De Santi S; Dinkelborg LM; Stephens AW
    J Nucl Med; 2020 Jun; 61(6):920-927. PubMed ID: 31712324
    [No Abstract]   [Full Text] [Related]  

  • 73. Quantitative
    Zhao Q; Liu M; Ha L; Zhou Y;
    Front Neurol; 2019; 10():486. PubMed ID: 31156534
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [
    Blazhenets G; Soleimani-Meigooni DN; Thomas W; Mundada N; Brendel M; Vento S; VandeVrede L; Heuer HW; Ljubenkov P; Rojas JC; Chen MK; Amuiri AN; Miller Z; Gorno-Tempini ML; Miller BL; Rosen HJ; Litvan I; Grossman M; Boeve B; Pantelyat A; Tartaglia MC; Irwin DJ; Dickerson BC; Baker SL; Boxer AL; Rabinovici GD; La Joie R
    J Nucl Med; 2023 Dec; 64(12):1980-1989. PubMed ID: 37918868
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tau PET With
    Huang CC; Hsiao IT; Huang CY; Weng YC; Huang KL; Liu CH; Chang TY; Wu HC; Yen TC; Lin KJ
    Front Neurol; 2019; 10():503. PubMed ID: 31191427
    [No Abstract]   [Full Text] [Related]  

  • 76. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.
    Chiotis K; Carter SF; Farid K; Savitcheva I; Nordberg A;
    Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1492-506. PubMed ID: 26130168
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Optimal Reference Region to Measure Longitudinal Amyloid-β Change with
    Bullich S; Villemagne VL; Catafau AM; Jovalekic A; Koglin N; Rowe CC; De Santi S
    J Nucl Med; 2017 Aug; 58(8):1300-1306. PubMed ID: 28183994
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cortical Amyloid β Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment.
    Chung JK; Plitman E; Nakajima S; Chakravarty MM; Caravaggio F; Gerretsen P; Iwata Y; Graff-Guerrero A;
    J Geriatr Psychiatry Neurol; 2016 May; 29(3):149-59. PubMed ID: 26400248
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluation of [
    Baker SL; Provost K; Thomas W; Whitman AJ; Janabi M; Schmidt ME; Timmers M; Kolb HC; Rabinovici GD; Jagust WJ
    J Cereb Blood Flow Metab; 2021 Dec; 41(12):3302-3313. PubMed ID: 34259071
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.